RegulatoryMay 7, 2026, 08:32 AM
Quoin Pharma QRX003 Gets FDA Fast Track; Single Phase 3 Study May Suffice
AI Summary
Quoin Pharmaceuticals announced significant regulatory advancements for QRX003 in Netherton Syndrome, including U.S. FDA Fast Track Designation and a constructive Type C meeting suggesting a single Phase 3 study could support marketing approval. The company also filed for Breakthrough Medicine Designation in Saudi Arabia and Orphan Drug Designation in Japan, with MHLW confirming Fast Track review eligibility. Quoin reported a Q1 2026 net loss of approximately $5 million, with $14 million in cash, expected to fund operations into 2027, and is on track for a potential NDA filing in 2027.
Key Highlights
- U.S. FDA granted Fast Track Designation to QRX003 lotion (4%) for Netherton Syndrome.
- FDA indicated a single Phase 3 study may suffice for QRX003 U.S. marketing approval.
- Quoin filed for Breakthrough Medicine Designation with Saudi FDA for QRX003.
- Submitted Orphan Drug Designation to Japanese MHLW for QRX003, confirmed for Fast Track review.
- Q1 2026 net loss was approximately $5 million, compared to $3.8 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled approximately $14 million as of March 31, 2026.
- R&D expenses increased to $3.43 million in Q1 2026 from $2.37 million in Q1 2025.
- On track to complete QRX003 Phase 3 recruitment by end of 2026, with potential NDA filing in 2027.